The ImmunityBio, Inc. - line shows up 2 times in the congressional disclosure record in 2026, filed by 1 member: 2 purchases against 0 sales. On balance the chamber has been net buyers, and the purchases sit down 12.8% against the latest close.
*Purchases only, weighted by the midpoint of each disclosed dollar band and marked to the latest close. Filings report a range, never a share count, so this follows the stock rather than anyone's position size.
Reported a IBRX purchase in filings from the last 90 days, newest first. 1 member.
| Date | Member | Type | Amount | Est. price | Latest close | Return |
|---|---|---|---|---|---|---|
| 2026-09-30 | Lisa McClain | BUY | $1K–$15K | $9.44 | $7.81 2026-10-26 | -17.3% |
| 2026-09-28 | Lisa McClain | BUY | $1K–$15K | $8.52 | $7.81 2026-10-26 | -8.3% |
Buys are marked to the latest close and treated as open. A sell tagged rt closes an earlier disclosed buy in the same name. exit shows how the stock moved after the member sold.
1 member of the U.S. House and Senate has disclosed ImmunityBio, Inc. - transactions under the STOCK Act — 2 purchases and 0 sales. The full member-by-member breakdown, with dates and dollar ranges, is in the table above.
1 member disclosed a IBRX purchase in the last 90 days — most recently Lisa McClain on 2026-09-30. See the "Lawmakers who bought IBRX recently" section above for the dated list.
Notional-weighted, lawmakers' disclosed IBRX buys are down 12.8% versus the latest close of $7.81. Each trade's own return — and realized round-trips on matched sells — is in the Return column.
Yes. Under the 2012 STOCK Act, members of Congress may buy and sell individual stocks but must publicly disclose each transaction within 45 days. Bargo surfaces those filings so you can see who traded IBRX and how it performed.